Skip to content

Efficacy of High-flow Nasal Oxygen in Preventing Hypoxia During Gastrointestinal Endoscopy: a Retrospective Cohort Study

Efficacy of High-flow Nasal Oxygen in Preventing Hypoxia During Gastrointestinal Endoscopy: a Retrospective Cohort Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06710613
Enrollment
900
Registered
2024-11-29
Start date
2024-11-01
Completion date
2025-06-01
Last updated
2024-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypoxia

Keywords

High flow nasal cannula oxygen

Brief summary

During painless gastroscopy, the occurrence of hypoxia is a critical concern, especially under intravenous anesthesia using propofol. This study aimed to investigate the incidence of hypoxia during painless gastroscopy and evaluate preventive measures.

Detailed description

From June 15 th 2023 to August 15th 2023, 900 patients who underwent elective gastroscopy in the Renji Hospital, Shanghai Jiao Tong University School of Medicine were selected. They were divided into the high flow nasal cannula oxygen group and the conventional nasal cannula oxygen group by oxygen inhalation. Patient demographics, Mallampati class, and other relevant factors were compared between the two groups. Primary outcomes included the incidence hypoxia (SpO2 \< 90%), while secondary outcomes included subclinical respiratory depression, and adverse events related to nasal oxygen cannula.

Interventions

None listed

Sponsors

Fengli Liu
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

: * Patients aged 18 to 70 * Undergoing painless gastroscopy under intravenous anesthesia

Exclusion criteria

: * Severe respiratory disease * History of nasal bleeding or mucosal injury * Emergency cases * Pregnant or lactating female

Design outcomes

Primary

MeasureTime frameDescription
incidence of hypoxia60 secondsSpO2 levels less than 90%

Secondary

MeasureTime frameDescription
the incidence of subclinical respiratory depression and adverse events30 minutethe incidence of and subclinical respiratory depression (SpO2 levels between 90% and less than 95%) and adverse events(mouth or nasal dryness, headache, nasal mucosal injury with bleeding, barotrauma. )

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026